McCulloch Kevin sold $141K of XERS
McCulloch Kevin (See Remarks) sold 15,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $9.41 ($0.14M total) on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest but may influence short‑term sentiment; investors may watch for further insider activity.
Market read
Primary insider sale news with limited material impact; relevant for short‑term traders monitoring XERS.
What to watch
The officer retains a large holding of 1.6 million shares, indicating continued confidence.
Background
SEC Form 4 filings disclose insider transactions and are primary sources for such events.
Ticker impact
Officer Kevin McCulloch sold 15,000 shares of Xeris Biopharma for $141,120 on Oct 1 via a 10b5-1 plan.
likely pressure as the market prices in the insider sell
A 10b5-1 sale by an officer, though modest in size, can be interpreted as a lack of confidence and may trigger short-term selling.
Market effects
Minimal impact on the broader biotech sector; the sale is company‑specific.
No regional effect.
Limited to investors tracking Xeris Biopharma.
Counterpoint
The sale may be routine under a pre‑arranged plan and not indicative of future performance.
Key entities
- CompanyXeris Biopharma Holdings, Inc.
Biopharma company listed on Nasdaq.
- OfficerKevin McCulloch
Company officer executing a 10b5-1 sale.
